EA201490032A1 - Лиофилизированные препараты fgf-18 - Google Patents

Лиофилизированные препараты fgf-18

Info

Publication number
EA201490032A1
EA201490032A1 EA201490032A EA201490032A EA201490032A1 EA 201490032 A1 EA201490032 A1 EA 201490032A1 EA 201490032 A EA201490032 A EA 201490032A EA 201490032 A EA201490032 A EA 201490032A EA 201490032 A1 EA201490032 A1 EA 201490032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparations
fgf
lyophylized
relates
lyophilized
Prior art date
Application number
EA201490032A
Other languages
English (en)
Other versions
EA024937B1 (ru
Inventor
Алессандра Черрети
Алессандра Дель Рио
Original Assignee
Арес Трейдинг С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47356563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490032(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Арес Трейдинг С.А. filed Critical Арес Трейдинг С.А.
Publication of EA201490032A1 publication Critical patent/EA201490032A1/ru
Publication of EA024937B1 publication Critical patent/EA024937B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к области фармацевтических препаратов. Более конкретно, оно относится к лиофилизированным препаратам соединения фактора роста фибробластов 18 (FGF-18) и к способам получения таких препаратов. Лиофилизированные препараты по изобретению стабильны при хранении в течение надлежащего периода времени. Их можно применять, после восстановления, для лечения патологий хряща, таких как остеоартрит или травма хряща.
EA201490032A 2011-06-17 2012-06-15 Лиофилизированные препараты fgf-18 EA024937B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170437 2011-06-17
US201161499216P 2011-06-21 2011-06-21
PCT/EP2012/061495 WO2012172072A1 (en) 2011-06-17 2012-06-15 Freeze-dried formulations of fgf-18

Publications (2)

Publication Number Publication Date
EA201490032A1 true EA201490032A1 (ru) 2014-05-30
EA024937B1 EA024937B1 (ru) 2016-11-30

Family

ID=47356563

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490032A EA024937B1 (ru) 2011-06-17 2012-06-15 Лиофилизированные препараты fgf-18

Country Status (31)

Country Link
US (2) US9326944B2 (ru)
EP (2) EP3056211A1 (ru)
JP (1) JP5981538B2 (ru)
KR (1) KR102019520B1 (ru)
CN (2) CN107715104A (ru)
AR (1) AR086956A1 (ru)
AU (1) AU2012268987B2 (ru)
BR (1) BR112013032400B1 (ru)
CA (1) CA2836667C (ru)
CL (1) CL2013003618A1 (ru)
CO (1) CO6940377A2 (ru)
CY (1) CY1117933T1 (ru)
DK (1) DK2720710T3 (ru)
EA (1) EA024937B1 (ru)
EC (1) ECSP14013157A (ru)
ES (1) ES2575732T3 (ru)
HR (1) HRP20160566T1 (ru)
HU (1) HUE028355T2 (ru)
IL (1) IL229977A (ru)
MX (1) MX338017B (ru)
MY (1) MY170630A (ru)
PE (1) PE20141265A1 (ru)
PL (1) PL2720710T3 (ru)
PT (1) PT2720710E (ru)
RS (1) RS54875B1 (ru)
SG (1) SG195021A1 (ru)
SI (1) SI2720710T1 (ru)
TW (1) TWI527590B (ru)
UA (1) UA113174C2 (ru)
WO (1) WO2012172072A1 (ru)
ZA (1) ZA201308698B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
SG11201604972TA (en) 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
CN107921095A (zh) * 2015-08-13 2018-04-17 默克专利有限公司 包含fgf‑18化合物的复方组合物
FI3706710T3 (fi) * 2017-11-10 2024-07-08 Novartis Ag Pitkäkestoisesti vapautuvia formulaatioita nivelensisäisiin käyttötarkoituksiin
CN109836487B (zh) * 2019-03-01 2022-06-17 重庆派金生物科技有限公司 一种人成纤维细胞生长因子18及其可溶性重组表达方法、制备方法、制剂和应用
CN112121150A (zh) * 2019-06-24 2020-12-25 杭州生物医药创新研究中心 一种成纤维细胞生长因子10冻干粉
CN113304063A (zh) * 2021-04-23 2021-08-27 四川省恩乐生物工程有限公司 一种用于肌肤美容抗衰老的组合物及其制备方法
CN118310835A (zh) * 2024-04-16 2024-07-09 杭州百凌生物科技有限公司 一种质控品冻干粉及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217954A (en) * 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
GB9015824D0 (en) 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
IL129379A (en) 1996-10-16 2008-12-29 Zymogenetics Inc Fibroblast growth factor homologues
CN1184673A (zh) * 1996-12-13 1998-06-17 中国医科大学 Fgf粗提多肽生长因子混合物及其提取工艺
AU6411199A (en) 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
JP5209161B2 (ja) 1999-12-02 2013-06-12 ザイモジェネティクス, インコーポレイテッド 腺維芽細胞成長受容体−3又は−2を発現する細胞を標的化するための方法
CN1303714A (zh) * 2000-01-13 2001-07-18 重庆多泰制药有限公司 Ii型胶原蛋白口服胃溶制剂
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
EP1551426B1 (en) * 2002-10-07 2014-06-25 ZymoGenetics, Inc. Methods of administering fgf18
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
CA2567309A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
JP5948627B2 (ja) * 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
JP4729740B2 (ja) * 2006-01-11 2011-07-20 独立行政法人産業技術総合研究所 受容体特異性を変化させたミュータント増殖因子およびそれを含有する医薬組成物
SI1986612T1 (sl) 2006-02-07 2013-01-31 Shire Human Genetic Therapies, Inc. Stabilizirana spojina glukocerebrosidaze
AU2007287510B2 (en) 2006-08-25 2012-08-30 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
CN101663046B (zh) * 2007-03-30 2017-07-28 Ambrx公司 经修饰fgf‑21多肽和其用途
CN104163864B (zh) * 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
CN101181280B (zh) * 2007-11-23 2010-07-14 深圳万乐药业有限公司 吡柔比星冻干制剂及其制备方法
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物

Also Published As

Publication number Publication date
CA2836667C (en) 2020-01-14
MX338017B (es) 2016-03-29
EP2720710A1 (en) 2014-04-23
KR20140041600A (ko) 2014-04-04
PL2720710T3 (pl) 2016-09-30
AU2012268987B2 (en) 2016-09-08
EP2720710B1 (en) 2016-03-23
CY1117933T1 (el) 2017-05-17
US20140121162A1 (en) 2014-05-01
PE20141265A1 (es) 2014-09-29
EP3056211A1 (en) 2016-08-17
TWI527590B (zh) 2016-04-01
IL229977A (en) 2017-01-31
TW201302217A (zh) 2013-01-16
US9326944B2 (en) 2016-05-03
MX2013014894A (es) 2014-09-01
UA113174C2 (xx) 2016-12-26
NZ617992A (en) 2015-09-25
ZA201308698B (en) 2016-02-24
US20160228374A1 (en) 2016-08-11
JP5981538B2 (ja) 2016-08-31
AR086956A1 (es) 2014-02-05
BR112013032400B1 (pt) 2021-07-20
SG195021A1 (en) 2013-12-30
WO2012172072A1 (en) 2012-12-20
EA024937B1 (ru) 2016-11-30
ES2575732T3 (es) 2016-06-30
CL2013003618A1 (es) 2014-07-04
MY170630A (en) 2019-08-21
KR102019520B1 (ko) 2019-11-04
RS54875B1 (sr) 2016-10-31
BR112013032400A2 (pt) 2016-11-22
ECSP14013157A (es) 2014-02-28
SI2720710T1 (sl) 2016-07-29
HUE028355T2 (en) 2016-12-28
JP2014522807A (ja) 2014-09-08
DK2720710T3 (en) 2016-06-27
CA2836667A1 (en) 2012-12-20
HRP20160566T1 (hr) 2016-06-17
CO6940377A2 (es) 2014-05-09
CN103619347A (zh) 2014-03-05
CN107715104A (zh) 2018-02-23
PT2720710E (pt) 2016-06-17

Similar Documents

Publication Publication Date Title
EA201490032A1 (ru) Лиофилизированные препараты fgf-18
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201490853A1 (ru) Противовирусные соединения
EA201492053A1 (ru) Белки фактора роста фибробластов 21
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201890333A1 (ru) Противовирусные соединения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
EA202092627A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2016008442A (es) Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.
EA201300443A1 (ru) Способ получения дигидроптеридинонов и их промежуточных продуктов
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
EA201692550A1 (ru) Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM